Shattuck Labs Announces Participation in Upcoming September Conferences
September 01 2022 - 4:15PM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that company management will participate in two investor
conferences in September 2022.
Presentation Details
Conference: Citi’s 17th Annual BioPharma ConferenceFormat:
Targeted Oncology panel discussion with covering analyst Yigal
NochomovitzPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s
Chief Executive OfficerDate: September 8, 2022Time: 2:40 p.m.
ET
Conference: H.C. Wainwright 24th Annual Global Investment
ConferenceFormat: Corporate PresentationPresenter: Taylor
Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate:
September 12, 2022Time: 7:00 a.m. ET
A live webcast of the presentations will be available on the
Events & Presentations section of the Company’s website. A
replay of the webcast will be archived for up to 90 days following
the presentation date.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L)
program, which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in
multiple Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.ShattuckLabs.com.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024